Skip to content
10-K

Annual Report

LAVA Therapeutics NV

0001558370-25-003988

← back to feed
Filed
Mar 28, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 21, 2025 26.31M sh
Shares Diluted FY 2024 · Dec 31, 2024 26.83M sh
Shares Diluted FY 2024 · Dec 31, 2023 26.73M sh
Capex FY 2024 · Dec 31, 2024 $23K
Capex FY 2024 · Dec 31, 2023 $731K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$19.54M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$40.28M
Long Term Debt FY 2024 · Dec 31, 2024 $4.89M
Long Term Debt FY 2024 · Dec 31, 2023 $5.28M
Short Term Debt FY 2024 · Dec 31, 2024 $4.89M
Short Term Debt FY 2024 · Oct 31, 2024 $4.9M
Short Term Debt FY 2024 · Dec 31, 2023 $5.28M
Short Term Investments FY 2024 · Dec 31, 2024 $41.56M
Short Term Investments FY 2024 · Dec 31, 2023 $51.34M
Cash And Equivalents FY 2024 · Dec 31, 2024 $35.02M
Cash And Equivalents FY 2024 · Dec 31, 2023 $44.23M
Stockholders Equity FY 2024 · Dec 31, 2024 $27.75M
Stockholders Equity FY 2024 · Dec 31, 2023 $51.36M
Stockholders Equity FY 2024 · Dec 31, 2022 $86.12M
Current Liabilities FY 2024 · Dec 31, 2024 $18.01M
Current Liabilities FY 2024 · Dec 31, 2023 $14.89M
Total Liabilities FY 2024 · Dec 31, 2024 $53.09M
Total Liabilities FY 2024 · Dec 31, 2023 $50.31M
Current Assets FY 2024 · Dec 31, 2024 $79.3M
Current Assets FY 2024 · Dec 31, 2023 $98.9M
Total Assets FY 2024 · Dec 31, 2024 $80.83M
Total Assets FY 2024 · Dec 31, 2023 $101.67M
Eps Diluted FY 2024 · Dec 31, 2024 −$0.94
Eps Diluted FY 2024 · Dec 31, 2023 −$1.57
Eps Basic FY 2024 · Dec 31, 2024 −$0.94
Eps Basic FY 2024 · Dec 31, 2023 −$1.57
Sga Expense FY 2024 · Dec 31, 2024 $13.23M
Sga Expense FY 2024 · Dec 31, 2023 $14.12M
Rd Expense FY 2024 · Dec 31, 2024 $28.45M
Rd Expense FY 2024 · Dec 31, 2023 $32.56M
Net Income FY 2024 · Dec 31, 2024 −$25.11M
Net Income FY 2024 · Dec 31, 2023 −$41.87M
Operating Income FY 2024 · Dec 31, 2024 −$29.69M
Operating Income FY 2024 · Dec 31, 2023 −$43.39M
Revenue FY 2024 · Dec 31, 2024 $11.98M
Revenue FY 2024 · Dec 31, 2023 $6.77M
Cost Of Revenue FY 2024 · Dec 31, 2023 $3.48M